Apixaban dvt pe trial download

By Shaktikree 2 Oct, 2012 0 Comments

Apixaban dvt pe trial

In the Apixaban for the Initial Management of Pulmonary Embolism and Deep- Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, we. The Apixaban for the Initial Management of Pulmonary Embolism and Deep -Vein Thrombosis as First-Line Therapy (AMPLIFY) trial. The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death.

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients. Recently, in the AMPLIFY-EXT trial, apixaban demonstrated superiority The qualifying diagnosis was DVT in two-thirds of the patients, PE in. Choose ELIQUIS® (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Graphic representing the AMPLIFY clinical trial.

Learn about ELIQUIS® (apixaban) for DVT/PE treatment and reduction in risk An Additional ELIQUIS Clinical Trial For Reducing the Risk of Recurrent DVT/PE . Oral apixaban noninferior to conventional treatment of acute venous The EINSTEIN-DVT trial: Rivaroxaban in acute deep-vein thrombosis. BACKGROUND: The AMPLIFY trial compared apixaban with Among patients with active cancer, recurrent VTE occurred in % and % of. Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively . In the ADVANCE-1 trial, apixaban mg daily was compared to.